Key result
Enteric-coated aspirin eliminated gastric injury caused by low-dose aspirin and substantially reduced injury from high-dose aspirin compared to plain aspirin in healthy volunteers.
Why the study?
Does enteric-coated aspirin prevent gastric mucosal damage compared to plain aspirin or placebo in healthy volunteers?
Population
Healthy volunteers
Comparison
Enteric-coated aspirin for 5 days vs Placebo or plain aspirin for 5 days
Design
RCT, Cross-over trial using Latin square design, Double-blind
Follow-up
5 days
Authors
Loading...
May support enteric-coated aspirin preference to limit gastric injury in low-dose users; confirms short-term benefit in healthy volunteers.
RCT
Double-blind
Latin square design cross-over
Does enteric-coated aspirin prevent gastric mucosal damage compared to plain aspirin or placebo in healthy volunteers?
Enteric-coating of aspirin virtually eliminates short-term gastric toxicity caused by low-dose aspirin in healthy volunteers, independent of prostaglandin synthesis inhibition.
Hawthorne et al. (1991) conducted an RCT in Aspirin-induced gastric mucosal damage. Enteric-coated aspirin vs. Plain aspirin and placebo was evaluated on Gastric damage assessed endoscopically and gastric mucosal bleeding. Enteric-coated aspirin eliminated gastric injury caused by low-dose aspirin and substantially reduced injury from high-dose aspirin compared to plain aspirin in healthy volunteers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: